Wolverine Trading
NBIX icon

Wolverine Trading’s Neurocrine Biosciences NBIX Stock Holding History

Wolverine Trading’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,200
Closed -$441K – 5190
2024
Q2 		$441K Sell
3,200
-2,000
-38% -$274K ﹤0.01% 2968
2024
Q1 		$717K Buy
+5,200
New +$710K ﹤0.01% 2505
2022
Q2 		– Sell
-9,700
Closed -$897K – 5307
2022
Q1 		$897K Buy
9,700
+5,500
+131% +$466K ﹤0.01% 2549
2021
Q4 		$355K Buy
4,200
+1,000
+31% +$92K ﹤0.01% 3920
2021
Q3 		$302K Sell
3,200
-3,200
-50% -$302K ﹤0.01% 4688
2021
Q2 		$620K Sell
6,400
-4,000
-38% -$383K ﹤0.01% 3382
2021
Q1 		$980K Sell
10,400
-6,500
-38% -$682K ﹤0.01% 2789
2020
Q4 		$1.61M Sell
16,900
-2,100
-11% -$203K ﹤0.01% 1908
2020
Q3 		$1.86M Buy
19,000
+1,700
+10% +$197K ﹤0.01% 1539
2020
Q2 		$2.17M Sell
17,300
-8,000
-32% -$884K 0.01% 1351
2020
Q1 		$2.32M Buy
25,300
+1,800
+8% +$176K 0.01% 1228
2019
Q4 		$2.52M Buy
+23,500
New +$2.46M 0.01% 1648
2019
Q2 		– Sell
-44,900
Closed -$3.96M – 4891
2019
Q1 		$3.96M Buy
44,900
+10,900
+32% +$911K 0.01% 1031
2018
Q4 		$2.33M Sell
34,000
-7,600
-18% -$728K 0.01% 1299
2018
Q3 		$5.12M Buy
41,600
+17,800
+75% +$2.02M 0.01% 946
2018
Q2 		$1.97M Hold
23,800
– – ﹤0.01% 1604
2018
Q1 		$1.97M Sell
23,800
-100
-0.4% -$8.45K ﹤0.01% 1604
2017
Q4 		$1.85M Buy
23,900
+20,200
+546% +$1.38M 0.01% 1612
2017
Q3 		$227K Sell
3,700
-19,600
-84% -$1.03M ﹤0.01% 3648
2017
Q2 		$1.08M Buy
+23,300
New +$1.13M ﹤0.01% 1679
2017
Q1 		– Sell
-19,400
Closed -$751K – 4743
2016
Q4 		$751K Buy
19,400
+2,300
+13% +$104K ﹤0.01% 2188
2016
Q3 		$861K Sell
17,100
-9,600
-36% -$478K ﹤0.01% 2021
2016
Q2 		$1.21M Buy
+26,700
New +$1.23M 0.01% 1442

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wolverine Trading's NBIX Position: Q3 2024 in Review

Wolverine Trading sold out of Neurocrine Biosciences (NBIX) in Q3 2024, closing a stake of 3,915 shares — an estimated $539K sold.

Wolverine Trading first reported a position in NBIX in Q4 2016 and held it in 12 quarters. The position peaked at $1.43M in Q3 2018. 574 funds tracked by Wall St. Rank hold NBIX as of Q3 2024.

  • Wolverine Trading reported no remaining Neurocrine Biosciences position as of Q3 2024 after selling out during the quarter.
  • Wolverine Trading sold 3,915 Neurocrine Biosciences shares in Q3 2024, an estimated $539K.
  • Wolverine Trading first reported a position in Neurocrine Biosciences in Q4 2016 and held it in 12 quarters.
  • Wolverine Trading's Neurocrine Biosciences position peaked at $1.43M in Q3 2018.
  • 574 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2024.

Based on Wolverine Trading's 13F filing for Q3 2024, filed 14 Nov 2024.